Economic Observation Network The Paltuzumab injection independently developed by Fosun Pharma has been approved for market launch, and its products simultaneously cover the markets of China, Europe, and America, verifying its international capabilities.

Product development progress:
On May 29, 2026, Fosun Pharma announced its independently developed pertuzumab injection (Hanbiyou) ®） Approved by the State Food and Drug Administration for marketing, it is used for the treatment of HER2 positive breast cancer This product has previously been approved by the US FDA and the European Union, marking the official formation of the HER2 "dual target" combination of the company's synchronized layout in the three major markets of China, the United States, and Europe 。

Industry status:
Company product Hanqu You ® It has become the first monoclonal antibody biosimilar drug in China to be approved in the three major markets of China, the United States, and Europe simultaneously This validates its global development and registration capabilities, and is a key indicator of Biotech's transition to Biopharma.

The above content is based on publicly available information and does not constitute investment advice.